ImmPACT Bio

Company Overview

Snapshot

Founded in November 2016, ImmPACT Bio operates with 11–50 employees. The company has raised $137 million across 4 funding rounds from 9 investors. In October 2024, ImmPACT Bio was acquired by Lyell Immunopharma.

Business overview

ImmPACT Bio is a clinical-stage biotechnology company focused on developing transformative chimeric antigen receptor (CAR) T-cell therapies for cancer patients who have exhausted other treatment options. The company's core technology utilizes logic-gate-based CAR T platforms designed to address key challenges in cancer treatment, including preventing antigen escape, mitigating "on-target off-tumor" toxicities, and overcoming the immunosuppressive tumor microenvironment. ImmPACT Bio operates within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Drugs Discovery & Development industries, with a focus on oncology and cell therapy.

Strategic signal

In October 2024, ImmPACT Bio was acquired by Lyell Immunopharma. This acquisition signifies a strategic consolidation in the CAR T-cell therapy space, with Lyell Immunopharma integrating ImmPACT Bio's clinical pipeline, including its dual-targeting CD19/CD20 CAR T-cell product candidate, IMPT-314, to strengthen its focus on next-generation cancer therapies. This move indicates a validation of ImmPACT Bio's technology and a potential acceleration of its therapeutic candidates towards market.

Company Intelligence Q&A

What was a significant corporate development for ImmPACT Bio in late 2024?

In October 2024, ImmPACT Bio was acquired by Lyell Immunopharma. This acquisition aimed to strengthen Lyell's clinical pipeline by adding ImmPACT Bio's dual-targeting CD19/CD20 CAR T-cell product candidate, IMPT-314.

What grant did ImmPACT Bio receive in February 2024?

In February 2024, ImmPACT Bio was awarded an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to support its Phase 1b/2 study evaluating IMPT-514, a CD19/CD20 bispecific CAR T-cell therapy for refractory lupus nephritis and systemic lupus erythematosus.

What was a key regulatory milestone for ImmPACT Bio in early 2023?

In January 2023, ImmPACT Bio received FDA clearance for its Investigational New Drug (IND) application for IMPT-314, a bispecific CAR T-cell therapy targeting B-cell lymphomas, with plans to initiate a Phase 1/2 clinical trial.

Who was appointed to ImmPACT Bio's Board of Directors in February 2023?

In February 2023, ImmPACT Bio appointed Biren Amin, M.B.A., to its board of directors, bringing his expertise in capital markets, finance, and corporate strategy to the company.

What was a significant funding round for ImmPACT Bio in January 2022?

In January 2022, ImmPACT Bio closed a Series B financing round, led by venBio.